---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-133091"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2024-12-04T23:59:59+00:00"
generated_at: "2026-05-29T08:43:27.433351+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Aptevo unveils preclinical bispecific APVO442 for prostate cancer; targets $14B market

## Summary
- APVO442 is a PSMA x CD3 bispecific antibody designed to treat prostate cancer.
- First molecule developed using Aptevo's ADAPTIR-FLEX platform.
- Prostate cancer market valued at ~$14B, expected to grow to $24B+ over ten years.
- Preclinical studies show tumor localization and reduced binding to circulating immune cells.
- Aims to address advanced-stage prostate cancer with improved safety and efficacy.

## SEC filing metadata
- accession: 0000950170-24-133091
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2024-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017024133091/0000950170-24-133091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017024133091/apvo-20241204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-133091
- JSON: https://secwatch.observer/filing/0000950170-24-133091.json
- Plain text: https://secwatch.observer/filing/0000950170-24-133091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.